Polatuzumab Vedotin
Bispecific Antibody
Li Zhimingantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Bispecific Antibody cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Elranatamab Pfizer | Phase 2 | B |
Mezigdomide Pfizer | Phase 2 | B |
DEXAMETHASONE Pfizer | Phase 2 | B |
Benadryl Pfizer | Phase 2 | B |
Cyclophosphamide Li Zhiming | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Polatuzumab Vedotin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →